Quality
Odyssey Therapeutics Appoints Pharmaceutical Leader Nia Tatsis, Ph.D., to Its Board of Directors
Odyssey Therapeutics; Nia Tatsis; Board of Directors; Vertex Pharmaceuticals; RIPK2 scaffolding inhibitor; autoimmune diseases; biopharmaceuticals; regulatory affairs; quality assurance
The Perfect Storm: Why 2025 Will Be the Year of GxP AI in Pharma
GxP AI, pharmaceutical manufacturing, regulatory compliance, data-driven innovation, quality management, drug development
FDA Issues Import Alerts for Two Chinese API Manufacturers Following Failed Inspections
FDA, import alert, Chinese API manufacturers, failed inspections, quality control, Wuhu Nuowei Chemistry, Chengdu Innovation Pharmaceutical
Novo Nordisk Invests $409M in New Quality Control Lab in Denmark
Novo Nordisk, quality control lab, Denmark, pharmaceutical investment, biotechnology
Advancements in Hematology: Shaping the Future of Blood Disorder Diagnosis and Treatment
Hematology, Blood Disorders, Sickle Cell Disease, Gene Therapy, Clinical Guidelines, Quality Improvement
FDA Raises Sterility and Quality Concerns at Mark Cuban’s Dallas Drug Compounding Facility
Mark Cuban, Cost Plus Drugs, FDA, sterility concerns, quality issues, drug compounding, Dallas facility
Mitigating Risks in mRNA Manufacturing: Strategies for Smooth Transition from Preclinical to Clinical Stages
mRNA manufacturing, risk management, preclinical to clinical transition, quality control, regulatory compliance, raw material selection, process automation, analytical methods.